/CRXTQ

CRXTQ Stock - Clarus Therapeutics Holdings, Inc.

Q: What is the analyst price target for CRXTQ?

Analyst price target information is not currently available for CRXTQ.

Q: What is CRXTQ's market cap?

Market capitalization information is not currently available for CRXTQ.

Healthcare|Drug Manufacturers - General|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Feb 28

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CRXTQ

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.68

52W High$3.94

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020
Revenue	$13.96M	$6.37M
Gross Profit	$11.24M	$-2,318,000
Gross Margin	80.5%	-36.4%
Operating Income	$-39,732,000	$-47,177,000
Net Income	$-56,512,000	$-11,049,000
Net Margin	-404.9%	-173.5%
EPS	$-8.04	$-0.51

Company Overview

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. On September 5, 2022, Clarus Therapeutics Holdings, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Visit Website

Earnings History & Surprises

CRXTQ

Beat Rate

67%

Last 3 quarters

Avg Surprise

+10.9%

EPS vs Estimate

Beats / Misses

2/1

Last 12 quarters

Latest EPS

$-0.24

Q3 2022

EPS Surprise History

Q3 21

No data

Q4 21

+67.9%

$-0.26vs$-0.81

Q2 22

-52.5%

$-0.61vs$-0.40

Q3 22

+17.2%

$-0.24vs$-0.29

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2023	Mar 28, 2023	$-0.19	—	—	—
Q4 2022	Dec 19, 2022	$-0.19	—	—	—
Q3 2022	Aug 18, 2022	$-0.29	$-0.24	+17.2%	✓ BEAT
Q2 2022	May 16, 2022	$-0.40	$-0.61	-52.5%	✗ MISS
Q4 2021	Nov 18, 2021	$-0.81	$-0.26	+67.9%	✓ BEAT
Q3 2021	Sep 17, 2021	—	$-0.83	—	—

Frequently Asked Questions about CRXTQ

What is CRXTQ's current stock price?

Clarus Therapeutics Holdings, Inc. (CRXTQ) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for CRXTQ?

No analyst price targets are currently available for this stock.

What sector is Clarus Therapeutics Holdings, Inc. in?

Clarus Therapeutics Holdings, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the OTC exchange.

What is CRXTQ's market cap?

Clarus Therapeutics Holdings, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does CRXTQ pay dividends?

No, Clarus Therapeutics Holdings, Inc. does not currently pay a dividend to shareholders.